Carrick Therapeutics UK Ltd. has synthesized cyclin-dependent kinase 12 (CDK12) and/or cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, fragile X syndrome, muscular dystrophy, neurodegeneration, renal disorders and cancer.
Shanghai Leadopharma Technology Co. Ltd. has presented transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of irritable bowel syndrome, Crohn's disease, ulcerative colitis, pain and inflammation.
Scorpion Therapeutics Inc. has disclosed urea derivatives acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
University of Copenhagen has divulged 4-hydroxypyridine and 4-hydroxyquinoline derivatives acting as G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of fibrosis, diabetes, inflammatory and cognitive disorders.
Researchers from Guangzhou University of Chinese Medicine have presented preclinical results on a three-component vaccine, MPLA-Tn-KRN7000, as a tumor immunotherapeutic.
Poolbeg Pharma plc is expanding its evaluation of POLB-001 into oncology after findings indicated POLB-001's potential to dampen the pro-inflammatory cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapies for cancer.
Researchers from Therapyx Inc. and Intravacc BV assessed the potential of intranasal administration of a novel gonococcal vaccine candidate consisting of outer membrane vesicles (OMVs) and microsphere (ms)-encapsulated interleukin-12 (IL-12 ms). It was previously demonstrated that female mice can be immunized intravaginally with gonococcal OMVs plus IL-12 ms to induce anti-gonococcal antibodies and resistance to genital tract challenge with live Neisseria gonorrhoeae.
Researchers from Shanghai Institute of Materia Medica and affiliated organizations recently reported the synthesis and evaluation of novel α-pyrone III derivatives as potential therapeutic agents for the treatment of atherosclerosis.
Cantargia AB has completed a GLP toxicity study for its anti-inflammatory IL1RAP-binding antibody CAN-10, showing that CAN-10 was well tolerated when administered over 6 weeks.
“Short-lived organisms represent a fundamentally different evolutionary strategy, and the idiosyncrasies influencing their aging may not apply to longer-lived models, including humans,” researchers from Harvard Medical School wrote in the Jan. 11, 2023, issue of Science Advances.
In their paper, the authors reported insights into the genomics of longevity that took advantage of an unusual animal model: rockfish.
RSS
